SCHEMBL8524115

SCHEMBL8524115

O=c1[nH]c2cc(F)ccc2n1CCCCN1CCNC(c2ccc(F)cc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.41
▸ HTR7 P34969 3/20 0.40
▸ LMNA P02545 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ SLC22A2 O15244 1/20 0.39
▸ NR1I2 O75469 1/20 0.39
▸ GMNN O75496 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ ADRB2 P07550 1/20 0.39
▸ ADRB1 P08588 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ ADRA2A P08913 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ DRD2 P14416 1/20 0.39
▸ ADRA2B P18089 1/20 0.39
▸ ADRA2C P18825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13284828 0.72 DRD2 (0.70) HRH3HTR7LMNAMEN1SLC22A2
SCHEMBL8524117 0.71 PLD2 (0.36) HRH3OPRM1PLD2PLD1DAO
SCHEMBL27246575 0.70 HTR7 (0.60) HTR7LMNAHTR1AP2RX7
SCHEMBL8130804 0.69 LMNA (0.55) HTR7LMNAMEN1SLC22A2NR1I2
SCHEMBL2615288 0.69 DRD2 (0.79) HRH3HTR7LMNAMEN1SLC22A2
SCHEMBL4084811 0.68 DAO (0.55) LMNAMEN1CYP1A2CYP3A4ADORA3
SCHEMBL6844257 0.68 HTR7 (0.50) HRH3HTR7LMNAHTR1ADRD2
SCHEMBL2615289 0.68 DRD2 (0.63) HRH3HTR7LMNAMEN1SLC22A2
Flumeridone SCHEMBL636160 0.68 DRD2 (0.80) HTR7LMNAMEN1SLC22A2NR1I2
Flumeridone SCHEMBL11520064 0.67 DRD2 (0.79) HTR7LMNAMEN1SLC22A2NR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5889010-A PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS PFIZER INC. (US) 1999-03-30 — — US disclosed
Send feedback